+

WO1999013816A3 - Liposomal camptothecin formulations - Google Patents

Liposomal camptothecin formulations Download PDF

Info

Publication number
WO1999013816A3
WO1999013816A3 PCT/US1998/019086 US9819086W WO9913816A3 WO 1999013816 A3 WO1999013816 A3 WO 1999013816A3 US 9819086 W US9819086 W US 9819086W WO 9913816 A3 WO9913816 A3 WO 9913816A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
liposomal camptothecin
camptothecin
camptothecin formulations
liposomes
Prior art date
Application number
PCT/US1998/019086
Other languages
French (fr)
Other versions
WO1999013816A2 (en
Inventor
Karen Lewis Moynihan
David Lloyd Emerson
Su-Ming Chiang
Ning Hu
Original Assignee
Nexstar Pharmaceuticals Inc
Karen Lewis Moynihan
David Lloyd Emerson
Chiang Su Ming
Ning Hu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexstar Pharmaceuticals Inc, Karen Lewis Moynihan, David Lloyd Emerson, Chiang Su Ming, Ning Hu filed Critical Nexstar Pharmaceuticals Inc
Priority to US09/486,309 priority Critical patent/US6740335B1/en
Priority to BR9812316-5A priority patent/BR9812316A/en
Priority to NZ503293A priority patent/NZ503293A/en
Priority to AU93877/98A priority patent/AU751439B2/en
Priority to JP2000511445A priority patent/JP2003510239A/en
Priority to KR1020007002701A priority patent/KR100711315B1/en
Priority to CA002303366A priority patent/CA2303366A1/en
Priority to EP98946983A priority patent/EP1037610A4/en
Publication of WO1999013816A2 publication Critical patent/WO1999013816A2/en
Publication of WO1999013816A3 publication Critical patent/WO1999013816A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Liposomal encapsulated camptothecin formulations are provided. The liposomes have improved pharmacokinetics, enhanced efficacy as anti-tumor agents and provide an increased therapeutic index as compared to the free drug and topotecan. The formulations include liposomes comprising at least one phospholipid and a camptothecin or analog thereof.
PCT/US1998/019086 1997-09-16 1998-09-15 Liposomal camptothecin formulations WO1999013816A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US09/486,309 US6740335B1 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations
BR9812316-5A BR9812316A (en) 1997-09-16 1998-09-15 Formulations of liposomal camptothecin
NZ503293A NZ503293A (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations also comprising at least one phospholipid
AU93877/98A AU751439B2 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations
JP2000511445A JP2003510239A (en) 1997-09-16 1998-09-15 Liposomal camptothecin preparation
KR1020007002701A KR100711315B1 (en) 1997-09-16 1998-09-15 Liposomal Camptothecin Formulation
CA002303366A CA2303366A1 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations
EP98946983A EP1037610A4 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5908397P 1997-09-16 1997-09-16
US60/059,083 1997-09-16

Publications (2)

Publication Number Publication Date
WO1999013816A2 WO1999013816A2 (en) 1999-03-25
WO1999013816A3 true WO1999013816A3 (en) 2001-11-01

Family

ID=22020747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019086 WO1999013816A2 (en) 1997-09-16 1998-09-15 Liposomal camptothecin formulations

Country Status (8)

Country Link
EP (1) EP1037610A4 (en)
JP (1) JP2003510239A (en)
KR (1) KR100711315B1 (en)
AU (1) AU751439B2 (en)
BR (1) BR9812316A (en)
CA (1) CA2303366A1 (en)
NZ (1) NZ503293A (en)
WO (1) WO1999013816A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1121102E (en) 1998-09-16 2003-09-30 Alza Corp TOPOISOMERASE INHIBITORS APPROVED IN LIPOSOMA
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
IL153676A0 (en) 2000-06-30 2003-07-06 Inex Pharmaceuticals Corp Liposomal pharmaceutical compositions
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
AU2002246510B2 (en) * 2000-11-09 2007-09-20 Neopharm, Inc. SN-38 lipid complexes and methods of use
DE10157994A1 (en) * 2001-05-25 2003-01-02 G O T Therapeutics Gmbh Liposomally encapsulated hydrophobic active ingredients with a high active ingredient content> 50% and methods for producing pharmaceutical preparations which comprise liposomally encapsulated hydrophobic active ingredients
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
CN100367932C (en) * 2002-11-26 2008-02-13 吉里德科学公司 Method of drug loading in liposomes by gradient
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
WO2008070009A2 (en) * 2006-12-01 2008-06-12 Alza Corporation Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes
CN101209243B (en) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Liposome medicament and preparation thereof
TWI428135B (en) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
KR101130754B1 (en) 2010-06-25 2012-03-28 제일약품주식회사 Pharmaceutical compositions having improved solubility of poorly soluble tricyclic derivative compounds
FR2979239A1 (en) * 2011-08-25 2013-03-01 Trophos LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE
AU2013203682B2 (en) * 2011-08-25 2016-03-31 Trophos Liposome comprising at least one cholesterol derivative
US20140079773A1 (en) * 2012-09-18 2014-03-20 Comfort Care For Animals Llc Encapsulating liposomes
CA2891656C (en) 2012-11-20 2021-05-04 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
KR102162351B1 (en) 2018-11-08 2020-10-06 순천향대학교 산학협력단 Drug-conjugated compound and uses thereof
CN115721610B (en) * 2021-08-27 2024-10-25 沈阳药科大学 A 7-ethyl-10-hydroxycamptothecin compound liposome and its preparation method and application
CN116327701A (en) * 2023-02-27 2023-06-27 北京大学深圳医院（北京大学深圳临床医学院） Composite nano liposome for treating hepatic fibrosis and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721328A4 (en) * 1993-09-27 1997-09-17 Smithkline Beecham Corp Camptothecin formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1037610A4 *

Also Published As

Publication number Publication date
EP1037610A1 (en) 2000-09-27
NZ503293A (en) 2002-09-27
EP1037610A4 (en) 2004-07-07
KR100711315B1 (en) 2007-04-27
AU9387798A (en) 1999-04-05
AU751439B2 (en) 2002-08-15
CA2303366A1 (en) 1999-03-25
WO1999013816A2 (en) 1999-03-25
KR20010030599A (en) 2001-04-16
BR9812316A (en) 2001-03-20
JP2003510239A (en) 2003-03-18

Similar Documents

Publication Publication Date Title
WO1999013816A3 (en) Liposomal camptothecin formulations
WO2001095884A3 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
HUP0000150A2 (en) Peptide-lipid conjugates,liposomes and liposomal drug delivery
EP1198256A4 (en) Peptide-lipid conjugates, liposomes and liposomal drug delivery
AU5263496A (en) Targeted catheter drug administration
IL131259A0 (en) Topical drug preparations
HUP0000568A3 (en) Gel formulations for topical drug delivery containing 4-amino-2-ethoxymethyl-alpha, alpha-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol
AU6385396A (en) Drug mitochondrial targeting agents
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
PL328399A1 (en) Drug administration aid
HUP0000522A3 (en) N-acyl phoshpatidylethanolamine-mediated liposomal drug delivery
AU1302499A (en) Buffered drug formulations for transdermal electrotransport delivery
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
AU2219097A (en) Cyclosporin a formulations as nanoparticles
AU5266698A (en) Directional drug delivery stent
AU3287699A (en) Ultrasound-mediated drug delivery
AU6721598A (en) Dioxino derivatives and their use as therapeutic agents
AU4496900A (en) Improved drug delivery pack
AU5983900A (en) Combined preparations comprising antitumor agents
AU3999699A (en) Targeted liposomal drug delivery system
AU7377200A (en) Combination therapy including camptothecin
AU5326498A (en) Prodrug forms and new analogues of camptothecin, their use as medicaments
AU1656799A (en) Cationic drugs encapsulated in anionic liposomes
AU2337897A (en) Uniform drug delivery therapy
AU6309698A (en) Drugs containing aminopyridine derivatives as the active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 93877/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09486309

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2303366

Country of ref document: CA

Ref country code: CA

Ref document number: 2303366

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 503293

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020007002701

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 511445

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998946983

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998946983

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007002701

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWG Wipo information: grant in national office

Ref document number: 93877/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007002701

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载